Minhajat Rahmawati, Harjianti Tutik, Islam Itzar Chaidir, Winarta Sanjaya, Liyadi Yason Nikolaus, Bamatraf Nabilah Putri, Amanuddin Rabbaniyah
Internal Medicine Department, Hematology and Medical Oncology Division.
Medical Education Department.
Ann Med Surg (Lond). 2023 Jun 26;85(8):3931-3937. doi: 10.1097/MS9.0000000000000981. eCollection 2023 Aug.
This review aimed to evaluate the effect of bevacizumab on adverse events and the quality of life (QoL) from colorectal cancer (CRC) patient.
A literature search was conducted from PUBMED, MEDLINE databases and some valid literatures from another databases that published in the last 10 years, and the design is an observational and randomized controlled trial (RCT).
CRC is a malignancy, which happens in the colon or rectum. One of the therapy for CRC is by using bevacizumab, a monoclonal antibody. However, the usage of bevacizumab is still become a controversy because of its clinical complications. Several studies showed that bevacizumab could cause some adverse events in the cardiovascular, gastrointestinal, hematology, and others body systems and affect the CRC patient QoL. However, the clinical complication of this drug is also affected by the combination therapy regimen used.
The use of bevacizumab could cause some adverse event in different aspects, including cardiovascular, gastrointestinal, hematology, and others. Some of those are significant, but others are not. Besides that, using bevacizumab as a treatment regiment could also affect the QoL of CRC patients, but it is also affected by the combination therapy regimen used.
本综述旨在评估贝伐单抗对结直肠癌（CRC）患者不良事件及生活质量（QoL）的影响。
通过检索PUBMED、MEDLINE数据库以及过去10年在其他数据库发表的一些有效文献进行文献检索，研究设计为观察性和随机对照试验（RCT）。
CRC是一种发生在结肠或直肠的恶性肿瘤。CRC的治疗方法之一是使用单克隆抗体贝伐单抗。然而，由于其临床并发症，贝伐单抗的使用仍存在争议。多项研究表明，贝伐单抗可在心血管、胃肠道、血液学及其他身体系统引发一些不良事件，并影响CRC患者的QoL。然而，该药物的临床并发症也受所采用的联合治疗方案影响。
使用贝伐单抗可能在不同方面引发一些不良事件，包括心血管、胃肠道、血液学等方面。其中一些不良事件较为严重，但另一些则不然。除此之外，将贝伐单抗作为一种治疗方案使用也可能影响CRC患者的QoL，但这也受所采用的联合治疗方案影响。
